Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research

She will be based at the firm's Framingham, Massachusetts R&D site

Sanofi Rita Balice-GordonSanofi has appointed Rita Balice-Gordon as head of its neurobiology research therapeutic area.

She joins the French pharma firm from Pfizer, where she served as head of circuits, neurotransmitters and signaling in the its neuroscience and pain research unit.

During her time there she led a global team and was responsible for the company's worldwide research and development postdoctoral programme.

Prior to her time at Pfizer Balice-Gordon was professor of neuroscience and chair of the neuroscience graduate group in the Perelman School of Medicine at the University of Pennsylvania, where she currently holds an adjunct appointment.

In her new role at Sanofi Balice-Gordon will based at the firm's Framingham, Massachusetts R&D site and lead research efforts associated with Sanofi's early portfolio in neurobiology, including neurodegeneration, neuroinflammation and central nervous system inherited diseases.

18th May 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...